QuantRx Biomedical Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QTXB research report →
Price Chart
About the company
QuantRx Biomedical Corporation is engaged in the creation and marketing of its patented miniature pads (PADs) and related over-the-counter (OTC) products within the United States. Additionally, the company is developing genomic diagnostic tools for the laboratory market, leveraging its proprietary lateral flow technologies, including the RapidSense single-step lateral flow test. The company's PAD products are designed to address a range of medical conditions such as hemorrhoids, mild vaginal infections, urinary incontinence, menstrual hygiene, and other general medical needs.
- CEO
- Shalom Z. Hirschman
- IPO
- 2004
- HQ
- Tualatin, OR, US
Get TickerSpark's AI analysis on QTXB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $118.05K
- P/E
- -0.08
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.01
- EV/EBITDA
- 0.00
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 18.98%
- ROIC
- 1016.23%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-43,383
- Net Income
- $-476,701-1.5%
- EPS
- $-0.01-1.7%
- OCF Growth
- +34.0%
- FCF Growth
- +34.0%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -2.04
- RSI (14)
- 52
- Avg Volume
- 24.98K
No earnings-call transcripts are available for QTXB yet.
- Free Float
- 27.1%
- Shares Outstanding
- 236.09M
- Float Shares
- 63.94M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 25, 12 | Hirschman Shalom | other | 150,000 |
| May 25, 12 | FLEMING WILLIAM H | other | 300,000 |
| May 25, 12 | FLEMING WILLIAM H | other | 300,000 |
| Mar 1, 12 | ABRAMS MICHAEL S | other | 0 |
| Mar 1, 12 | ABRAMS MICHAEL S | other | 0 |
| Apr 30, 10 | PINCO ROBERT G. | other | 0 |
| Apr 30, 10 | MOONEY PATRICK T | other | 0 |
| Nov 15, 08 | MOONEY PATRICK T | other | 1,250 |
| Dec 31, 09 | HAYES ARTHUR H JR | other | 12,500 |
| Dec 31, 09 | Hirschman Shalom | other | 12,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our QTXB coverage
Recent articles, reports, and earnings notes.
No research on QTXB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate QTXB report →